# Ipsen clinical trials: 293 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 293 trials with Ipsen as lead sponsor, 18 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ipsen: 293 rows for $14.65, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ipsen

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 293
- Recruiting or not yet: 18
- Read on: November 19, 2026

## Trials

The 25 newest of 293, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944144 | A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer... | Ipsen | Phase 1/2 | Not yet recruiting | Neoplasms, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944144) |
| October 30, 2026 | NCT07906639 | A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranor | Ipsen | Observational | Not yet recruiting | Primary Biliary Cholangitis (PBC) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906639) |
| August 21, 2026 | NCT07779252 | A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between... | Ipsen | Phase 3 | Recruiting | Moderate to Severe Glabellar Lines | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779252) |
| June 3, 2026 | NCT07623187 | A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in... | Ipsen | Phase 2/3 | Not yet recruiting | Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623187) |
| May 15, 2026 | NCT07588880 | A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC)... | Ipsen | Observational | Recruiting | Progressive Familial Intrahepatic Cholestasis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588880) |
| May 13, 2026 | NCT07585097 | A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment | Ipsen | Observational | Recruiting | Alagille Syndrome | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585097) |
| April 29, 2026 | NCT07556913 | Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy | Ipsen | Observational | Recruiting | Pregnancy Related | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07556913) |
| March 27, 2026 | NCT07497724 | Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC) | Ipsen | Observational | Active not recruiting | PFIC - Progressive Familial Intrahepatic Cholestasis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497724) |
| March 2, 2026 | NCT07441707 | A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours | Ipsen | Phase 1 | Active not recruiting | Low-grade Glioma | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441707) |
| February 27, 2026 | NCT07435428 | A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the... | Ipsen | Phase 3 | Active not recruiting | Moderate to Severe Glabellar Lines | 1,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435428) |
| February 23, 2026 | NCT07427797 | A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows | Ipsen | Phase 3 | Active not recruiting | Moderate to Severe Glabellar Lines | 309 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07427797) |
| February 4, 2026 | NCT07387549 | A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis | Ipsen | Phase 3 | Recruiting | Primary Sclerosing Cholangitis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387549) |
| January 2, 2026 | NCT07314164 | Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment | Ipsen | Observational | Recruiting | Neuroendocrine Tumors | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314164) |
| December 15, 2025 | NCT07282548 | Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies | Ipsen | Observational | Withdrawn | Follicular Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282548) |
| October 9, 2025 | NCT07213830 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in... | Ipsen | Phase 1/2 | Recruiting | Advanced Solid Tumor, Metastatic Solid Tumor | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213830) |
| October 9, 2025 | NCT07213817 | A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults... | Ipsen | Phase 1/2 | Recruiting | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213817) |
| September 25, 2025 | NCT07191704 | A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes... | Ipsen | Observational | Completed | PFIC - Progressive Familial Intrahepatic Cholestasis | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07191704) |
| September 22, 2025 | NCT07185919 | A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC)... | Ipsen | Observational | Recruiting | Progressive Familial Intrahepatic Cholestasis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185919) |
| July 3, 2025 | NCT07049887 | A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria) | Ipsen | Observational | Completed | Primary Biliary Cholangitis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07049887) |
| April 22, 2025 | NCT06937931 | A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults | Ipsen | Phase 2 | Recruiting | Cervical Dystonia | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06937931) |
| April 3, 2025 | NCT06908954 | A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After... | Ipsen | Phase 1 | Completed | Hepatic Impairment, Healthy | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06908954) |
| February 27, 2025 | NCT06850038 | A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are... | Ipsen | Observational | Recruiting | Alagille Syndrome | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06850038) |
| February 18, 2025 | NCT06833008 | A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours | Ipsen | Phase 1/2 | Active not recruiting | Advanced Solid Tumor | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06833008) |
| December 12, 2024 | NCT06730061 | A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) | Ipsen | Phase 3 | Active not recruiting | Primary Biliary Cholangitis | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06730061) |
| October 3, 2024 | NCT06625060 | A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults | Ipsen | Phase 2 | Active not recruiting | Episodic Migraine, Chronic Migraine | 670 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06625060) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 19 |
| Phase 1/2 | 11 |
| Phase 2 | 47 |
| Phase 2/3 | 7 |
| Phase 3 | 73 |
| Phase 4 | 18 |
| Not applicable | 1 |
| Observational | 117 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 207 |
| Terminated | 42 |
| Active not recruiting | 18 |
| Recruiting | 15 |
| Withdrawn | 8 |
| Not yet recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Acromegaly | 34 |
| Prostatic Neoplasms | 23 |
| Neuroendocrine Tumors | 17 |
| Muscle Spasticity | 15 |
| Torticollis | 11 |
| Carcinoma, Renal Cell | 11 |
| Liver Cirrhosis, Biliary | 8 |
| Stroke | 6 |
| Neoplasm Metastasis | 6 |
| Diarrhea | 5 |
| Breast Neoplasms | 5 |
| Gastro-enteropancreatic neuroendocrine tumor | 4 |
| Cholestasis, progressive familial intrahepatic 1 | 4 |
| Puberty, Precocious | 4 |
| Serotonin Syndrome | 4 |
| Colorectal Neoplasms | 4 |
| Cerebral Palsy | 4 |
| Small Cell Lung Carcinoma | 3 |
| Endometriosis | 3 |
| Myofascial Pain Syndromes | 3 |
| Myositis Ossificans | 3 |
| Urinary Bladder, Overactive | 3 |
| Stomach Neoplasms | 3 |
| Cognitive Dysfunction | 3 |
| Growth Disorders | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Employment agencies in the United States](https://specstream.ai/data/businesses/employment-agencies/united-states)
- [Chicken wings restaurants in the United States](https://specstream.ai/data/businesses/chicken-wings-restaurants/united-states)
- [B2B direct mail advertising companies in the United States](https://specstream.ai/data/businesses/b2b-direct-mail-advertising-companies/united-states)
- [Urology practices in the United States](https://specstream.ai/data/businesses/urology-practices/united-states)
- [Scale suppliers in the United States](https://specstream.ai/data/businesses/scale-suppliers/united-states)
- [Pathology practices in the United States](https://specstream.ai/data/businesses/pathology-practices/united-states)
